Biogen | BIIB - Current Assets


Biogen reported $9.19B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
ALKERMES USD 1.36B 570.52M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Bayer EUR 35.3B 2.39B Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
Esperion Therapeutics USD 459.46M 3.11M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Moderna USD 5.77B 774M Mar/2026
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Pfizer USD 42.82B 76M Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.16B 789M Mar/2026
Sanofi EUR 30.95B 8.99B Dec/2025
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Teva Pharmaceutical Industries USD 13.71B 236M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
United Therapeutics USD 2.87B 830.5M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026